Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Sells $356,160.00 in Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) Director Kim R. Tsuchimoto sold 8,904 shares of the company's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $356,160.00. Following the completion of the transaction, the director owned 11,486 shares in the company, valued at approximately $459,440. This represents a 43.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Monopar Therapeutics Stock Down 1.6%

Shares of MNPR traded down $0.77 during trading on Friday, reaching $46.48. The company's stock had a trading volume of 30,457 shares, compared to its average volume of 363,996. Monopar Therapeutics Inc. has a twelve month low of $1.72 and a twelve month high of $54.30. The company has a market cap of $284.46 million, a price-to-earnings ratio of -13.36 and a beta of 1.01. The company has a fifty day moving average of $35.86 and a two-hundred day moving average of $36.31.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $0.27. As a group, equities analysts forecast that Monopar Therapeutics Inc. will post -1.65 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. AlphaQuest LLC acquired a new position in shares of Monopar Therapeutics during the 1st quarter worth $44,000. JPMorgan Chase & Co. bought a new stake in shares of Monopar Therapeutics in the fourth quarter worth $45,000. Gerber LLC bought a new stake in Monopar Therapeutics during the first quarter worth $204,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Monopar Therapeutics in the first quarter valued at $328,000. Finally, Jane Street Group LLC acquired a new position in shares of Monopar Therapeutics in the first quarter valued at $377,000. 1.83% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

MNPR has been the subject of several analyst reports. HC Wainwright restated a "buy" rating and set a $40.00 price target on shares of Monopar Therapeutics in a report on Tuesday, April 1st. Cantor Fitzgerald started coverage on Monopar Therapeutics in a research note on Monday, July 7th. They issued an "overweight" rating and a $74.00 price objective on the stock. Wall Street Zen raised Monopar Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Jones Trading reiterated a "hold" rating on shares of Monopar Therapeutics in a report on Wednesday, April 2nd. Finally, Chardan Capital assumed coverage on Monopar Therapeutics in a research report on Monday, June 23rd. They set a "buy" rating and a $60.00 target price on the stock. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Monopar Therapeutics has an average rating of "Moderate Buy" and an average price target of $60.00.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.